Original article: general thoracicKi-67 expression and prognosis for smokers with resected stage i Non–Small cell lung cancer
Section snippets
Tissue samples
One hundred eighty-seven patients (120 men and 67 women) were enrolled. The group included 122 patients with adenocarcinoma and 65 with squamous cell carcinoma. All of the patients had undergone complete resection, involving complete lobectomy or complete segmentectomy with standard lymph node dissection, at the Department of Thoracic Surgery, Chiba University Hospital, between 1988 and 1993. Patients were followed there for at least 5 years after their operations, and informed consents were
Clinicopathologic features and prognosis
According to the Kaplan-Meier method the postoperative overall 5-year survival rate for patients with adenocarcinoma was 81.7% and that for squamous cell carcinoma patients was 68.4%.
Table 1 shows the postoperative overall 5-year survival rates for the patients and their relationships to several clinicopathologic factors, as calculated using the Kaplan-Meier method. In the group of smokers with adenocarcinoma, the following factors affected survival rates: smoking status (p < 0.0001), tumor
Comment
Since we reported that the cigarette smoking status before surgery was one of the most important clinical prognostic factors in stage I NSCLC [3], we have tried to find the specific factors that can explain this result. In the current study, we elucidate the fact that smoking status before surgery is a prognostic factor for patients with stage I pulmonary adenocarcinoma, but not for patients with stage I squamous cell carcinoma. We also found that the Ki-67 LI was a significant pathologic
Acknowledgements
The authors thank Tamiyo Taniguchi, Michiko Hanazono, Ayaka Sato, and Kazuko Abe for their technical assistance.
References (33)
Revisions in the international system for staging lung cancer
Chest
(1997)- et al.
Molecular pathogenesis of lung cancer
J Thorac Cardiovasc Surg
(1999) - et al.
Cyclins and cancer IIcyclin D and CDK inhibitors come of age
Cell
(1994) - et al.
Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67
J Immunol Methods
(1986) - et al.
Molecular biologic substaging of stage I lung cancer according to gender and histology
Ann Thorac Surg
(2000) - et al.
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
Adv Cancer Res
(1996) - et al.
Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer
Hum Pathol
(2002) - et al.
Characteristics and prognosis of resected T3 non-small cell lung cancer
Ann Thorac Surg
(2002) - et al.
Relation between the pathological nature and the growth rate of human tumors
Eur J Cancer
(1971) - et al.
Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit
Jpn J Cancer Res
(1991)
Smoking before surgery predicts poor long-term survival in patients with stage I non-small cell lung carcinomas
J Clin Oncol
A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21different roles of G1 cyclins in cell proliferation and prognosis
Cancer Res
Cancer cell cycles
Science
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
Int J Cancer
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
J Immunol
Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
Am J Pathol
Cited by (42)
Prognostic value of Ki-67 in stage I non-small-cell lung cancer: A meta-analysis involving 1931 patients
2019, Pathology Research and PracticeCitation Excerpt :On the basis of the inclusion criteria, a total of 103 studies were retrieved from the electronic databases PubMed, Cochrane Library, and Web of Science. After careful review, fifteen studies [14–28] including 1931 stage I NSCLC patients were eventually selected (Fig. 1). The characteristics of these studies are listed in Table 1.
Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma
2017, Pathology Research and PracticeLocally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
2016, Pathology Research and PracticeCitation Excerpt :Another potentially important result of our study is that the simultaneous presence of KRAS mutations and high Ki67 expression is related to a worse response to CRT. Ki67 is a reliable marker/parameter for measuring the proliferative activity of the cell and could be a useful prognostic marker in some cancer types [43,44]. A previous study of Jakob et al. [45] has demonstrated that low levels of Ki67 expression are associated with good response to CRT in rectal cancer, and our results are in line with this.
Clinical impact of ki-67 labeling index in non-small cell lung cancer
2013, Lung CancerCitation Excerpt :The rationale for the choice of cut-off values varied between the including papers. Thirteen papers did not explain how the cut-value was decided [31,33,34,42,44,45,47,49,53–55,57,58], three papers defined the median ki-67 labeling index value as cut-off point [32,36,41] and one study calculated and used the H-score median [52]. Seven studies referred to cut-off values used in previous articles [35,37–40,46,51], and one study used the best discriminatory value [48].